Showing posts with label toxicities. Show all posts
Showing posts with label toxicities. Show all posts
Tuesday, May 08, 2012
paywalled: Science behind cisplatin-induced nephrotoxicity in humans: A clinical study
Science behind cisplatin-induced nephrotoxicity in humans: A clinical study: Publication year: 2012
Objective To investigate the relationship between serum electrolyte changes and cisplatin induced nephrotoxicity.
Conclusions The present study demonstrates that, acute nephrotoxicity was observed in patients with different types of cancers undergoing cisplatin based chemotherapy due to electrolyte disturbances, when no corrective measures were initiated.
add your opinions
Cisplatin
,
electrolyte
,
kidney
,
nephrotoxicity
,
toxicities
Tuesday, March 27, 2012
open access (pdf) Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?
Underestimating Cardiac Toxicity in Cancer Trials:Lessons Learned?
Sunitinib (Sutent; Pfizer, New York, NY) represents one of the
most successful cancer therapies, with US Food and Drug Administration (FDA) approval for three malignancies and ongoing trials in more than 30 tumor types.1,2 It also represents an instructive example revealing how adverse events can be vastly underestimated. The purpose of this article is to critically evaluate the history of the underrecognition of the cardiac toxicity of sunitinib and to propose solutions to improve adverse event monitoring for future therapies.......
"Cardiac toxicity from a wide variety of tyrosine kinase inhibitors
is now recognized to be of importance, with toxicity observed
from both on- and off-target effects. In the case of sunitinib, which
inhibits more than 50 kinases, mechanisms likely include inhibition
of angiogenesis and disturbances of mitochondrial structure
and energy metabolism—both potentially similarly important for
tumor proliferation.11,13"
add your opinions
adverse effects
,
cardiology
,
heart
,
sunitinib
,
Sutent
,
toxicities
,
tyrosine kinase inhibitors
Saturday, February 04, 2012
open access: Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study - 45 pts
Blogger's Note: interesting study worth reading
Background
Conclusions
IOERT may be feasible and effective as a boosting technique for advanced and recurrent ovarian cancer. IOERT plus IP chemotherapy may achieve high locoregional disease control and survival benefit with a low risk of toxicity. Peripheral nerves in the IOERT field are dose-limiting structures requiring nerve protection policies or a dose compromise to ensure against severe neurological damage.
Patients
This study was a non-randomized trial and included retrospective analysis of 45 women with EOC who were treated with IOERT at the 1st Affiliated Hospital of the Medical College of Xi'an Jiaotong University between January 2000 and January 2010.........The mean follow-up time was 78 months (range: 11-123 months).........
Table 1
Total | PD | ILR | |
---|---|---|---|
Cases | 45 | 25 | 20 |
Histology type | |||
serous adenocarcinoma | 36 | 21 | 16 |
papillary adenocarcinoma | 9 | 4 | 4 |
CA-125 level | |||
≥ 35 U/ml | 38 | 20 | 18 |
< 35 U/ml | 4 | 3 | 1 |
unknown | 3 | 2 | 1 |
Conclusions
IOERT may be feasible and effective as a boosting technique to treat advanced and recurrent ovarian cancers. IOERT plus IP chemotherapy may achieve high locoregional disease control and survival benefit with a low risk of toxicity. However, careful attention should be paid to peripheral nerves as specific IOERT dose-limiting structures.
add your opinions
intraoperative electron beam radiation therapy
,
IOERT
,
radiation therapy
,
toxicities
Wednesday, February 01, 2012
abstract: Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial
Background: In the CALYPSO trial, carboplatin–pegylated liposomal doxorubicin (CD) demonstrated superior therapeutic index versus carboplatin–paclitaxel (CP) in patients with recurrent ovarian cancer. This paper reports the health-related quality of life (HRQoL) findings.
Conclusions: These patient-reported outcomes confirm the overall lower toxicity of CD versus CP. The improved disease-related outcomes achieved with CD were not at the expense of QoL.
add your opinions
Calypso trial
,
Carboplatin
,
doxil
,
longterm side effects
,
Paclitaxel
,
QOL
,
quality of life
,
Taxol
,
toxicities
Friday, January 27, 2012
abstract: Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer (total 6 patients/phase 1)
Abstract:
This study was designed to determine the maximum tolerated dose and toxicity profile of belotecan in combination with oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer, fallopian tubal cancer, and primary peritoneal cancer.
"....Thus, the maximum tolerated dose was reached (50 mg of oral etoposide) and the trial was terminated. The response was evaluable in nine patients and an objective response was observed in four patients (44%) including two complete responses."
add your opinions
Belotecan
,
fallopian tube
,
oral etoposide
,
ovarian primary peritoneal cancer
,
platinum resistant
,
toxicities
Tuesday, June 28, 2011
Friday, January 21, 2011
Saturday, December 18, 2010
Mechanism of action and toxicities of purgatives used for colonoscopy preparation
Take home message: Although generally safe and effective, colonic purgatives have both acute and permanent toxicities. The safest preparations utilize PEG combined with a balanced electrolyte solution. Limitations of this preparation center on the volume required and poor taste. Alternative formulations are now available; however, those using sodium phosphate have fallen out of favor due to a risk of renal toxicity
Read More: http://informahealthcare.com/doi/abs/10.1517/17425255.2011.542411
Read More: http://informahealthcare.com/doi/abs/10.1517/17425255.2011.542411
add your opinions
colon
,
kidney
,
purgatives
,
renal
,
toxicities
Subscribe to:
Posts
(
Atom
)